Browsing Tag
George D. Yancopoulos
7 posts
Regeneron to acquire 23andMe’s core assets for $256m amid court-supervised bankruptcy sale
Regeneron to acquire 23andMe’s core assets for $256M in a court-supervised deal. Learn how this biotech merger impacts DNA data privacy, investor sentiment, and the future of genetics.
Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission…
Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2
US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2…
Dupixent delivers positive results in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of…
Dupixent receives FDA approval for treatment of moderate-to-severe asthma
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration…
FDA approves updated label for Regeneron’s EYLEA treating wet AMD
In a significant development for ophthalmic care, Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug…
Teva and Regeneron report positive Phase 3 results for Fasinumab in osteoarthritis pain management
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced successful outcomes from their phase 3 study of fasinumab, a…